New report data shows the global precision medicine market is valued at $119 billion in 2025 and is expected to hit $537 billion by 2035. That is a CAGR of roughly 16% over the next decade. North America currently dominates with 54% market share. The growth is mainly coming from AI adoption, genomic testing, and targeted therapies. Oncology remains the biggest application segment. Some company specifics mentioned in the report: * Novartis is pushing radioligand therapy for prostate cancer. * Vertex Pharmaceuticals has a cystic fibrosis therapy projected to do $8.3 billion in sales. * Nvidia and Mayo Clinic launched an AI platform for precision oncology in August. * Quest Diagnostics and Qiagen are expanding companion diagnostics. The main downside noted is high development costs, which makes it hard for smaller manufacturers to compete against the big pharmaceutical companies.